Importance The absolute benefit of chemotherapy for all patients with stage I triple-negative breast cancer (TNBC) is unclear, and biomarkers are not currently available for selecting patients with an excellent outcome for whom neoadjuvant or adjuvant chemotherapy may have negligible benefit. High ...
Subjects exer- cise in antechamber for 10 能II。 小气候和锻炼协议。 在前室服从锻炼cise为10 [translate] aPrognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. 预断因素在及早阶段三倍消极乳腺癌: 教训和极限从临床实践。 [translate] ...
aTriple-negative breast cancer: epidemiology and management options. 三倍消极乳腺癌: 流行病学和管理选择。[translate] aIt features two white lacquered domed dials 它以二个白色被上漆的半球形的拨号盘为特色[translate] aRecurrent early-stage triple-negative breast cancer. 正在翻译,请等待...[translate]...
Triple-negative breast cancer (TNBC) accounts for approximately 15%-20% of breast cancers diagnosed worldwide, which amounts to almost 200000 cases each year. Although historically TNBC is considered difficult to treat with a poor prognosis, there is emerging evidence showing excellent response ...
Distribution of Stage IV, Node-Positive, Estrogen-Receptor Positive, and Triple-Negative Breast Cancers View LargeDownload Table 4. Deaths Due to Stage I Breast Cancer at 7 Years View LargeDownload Table 5. Deaths Due to Breast Cancer Among Women With Small-Sized Tumors of 2.0 cm or Less ...
187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain meta... R Bartsch,AS Berghoff,J Furtner,... - 《Esmo Open》 被引量: 0发表: 2024年 LBA4 Datopotamab deruxtecan (Dato-DXd), ...
Triple-negative breast cancer (TNBC) comprises 10-15% of newly-diagnosed early-stage breast cancer. Most TN tumors are high grade and have a high incidence of recurrence and distant metastases. Patients with early stage TNBC usually do not receive any maintenance systemic therapy beyond standard ...
Breast cancer risk factors were correlated with time to BCBM on Cox proportion hazard analysis. The study cohort comprised 121 BCBM patients, with median interval time to BCBM of 46 months. Times to BCBM for Her2+/2HR+, Her2+, Her2−/HR+, and triple-negative (TNBC) subtypes were 70...
Merck’s anti-PD-1 therapy, met its overall survival (OS) endpoint, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients...
[translate] aLoss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. PTEN表示损失在三倍消极乳腺癌同IGFBP2表示、更加年轻的年龄和后期阶段联系在一起。[translate]